anayamalik, Author at European Medical Journal - Page 14 of 96

Hospitalizations Fall in Chronic Lymphocytic Leukemia Thanks to Continuity of Care

Patients with chronic lymphocytic leukemia (CLL) who consistently saw the same oncologist or hematologist experienced significantly fewer emergency room visits and hospitalizations, according to a large real-world study of nearly 6,000 individuals treated with covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy.

Alzheimer’s Studies Evolve with Bigger, Slower Trials

Randomized clinical trials in Alzheimer’s disease have grown substantially in scale and complexity over the past three decades, with modern studies increasingly designed to capture slower and more subtle therapeutic effects.

Interferon Nasal Spray Shows Protective Effect Against COVID-19

Daily prophylaxis with interferon-alpha (IFN-α) nasal spray significantly reduced the risk of COVID-19 infection in adult patients with cancer, according to findings from a randomized, double-blinded, placebo-controlled trial.

Remote Care Halves COPD Burden and Sharpens Inhaler Technique

Telemedicine follow-up significantly improved quality of life and inhaler use techniques among patients with advanced chronic obstructive pulmonary disease (COPD), according to a randomized controlled trial.

ChatGPT Outperforms Google in SLE Biologic Therapy Guidance

ChatGPT demonstrates higher accuracy and completeness than Google Web Search when providing information about biologic therapy for systemic lupus erythematosus (SLE), according to a new comparative study.

Chronic Bronchitis Significantly Associated With Psoriasis

Adults with psoriasis may be more likely to also have chronic bronchitis, according to new U.S. population-based findings.

Obesity-Restricted Benefits of GLP-1 Therapy in Lung Cancer

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes and weight reduction, may offer significant benefits in improving outcomes for patients with non-small cell lung cancer (NSCLC), according to new clinical and preclinical evidence.

GLP-1 Agonists Show Motor Benefits in Parkinson’s

Emerging evidence suggests that GLP-1 receptor agonists, widely used for type 2 diabetes mellitus (T2DM), may offer therapeutic benefits in Parkinson’s disease (PD).

Legionnaires’ Pneumonia Prognosis Better in ICU

Severe Legionnaires’ disease requiring intensive care unit (ICU) admission shows improved survival compared to earlier reports, according to a multicenter retrospective cohort study of French patients.

ILD Progression in Rheumatoid Arthritis Linked to Mortality

Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is increasingly recognized as a major factor influencing long-term outcomes in affected patients, with new data showing that disease progression and specific lung patterns significantly impact mortality.